In this month’s video, I look at the technical trends developing in stocks and bonds. Chart review includes analysis of large-cap, small cap, international, Treasury bonds, and gold prices. Observations of risk and reward are noted throughout with an emphasis on moving averages as a source of support or resistance. Recorded on April 11, 2017.
I’m normally an optimistic, “glass-half-full” kind of guy. I roll my eyes every time I see a headline decrying the next market crash or cataclysmic event that will cripple the global economy. I’m quick to discern speculation from truths and prefer taking the opposite side of most mainstream assumptions.
It’s not that I see everything through rose colored glasses, but rather that I have found an unruffled approach to be a strong foundation for better decision making. Navigating the markets with a calm and calculated strategy produces far superior returns than simply worrying about what dangers might lurk around every corner. Read more
The volatility in the biotech space over the last two years has been quite a sight to behold. I’m not strictly speaking of volatility in terms of downside either. There has been money to be made on both sides of the market for those that have been nimble in their trades.
Most ETF investors are probably familiar with trading the iShares NASDAQ Biotechnology ETF (IBB). This market-cap weighted giant has $8.2 billion dedicated to a basket of 164 stocks in the biotech research and medical services fields. As you can see on the chart below, this index has been on a rollercoaster ride of whipsaws in both directions over the last year.
Clients and readers often ask my opinion about an investment relative to its 200-day moving average. This trend line is one of the most common foundations of simple technical analysis.
In fact, the 200-day moving average has deep-rooted meaning to my family legacy. My grandfather Dick Fabian was one of the first investors to pioneer a trend following system based on this measurement. Read more
This time of year is always an opportune moment to reflect on the last twelve months and the journey that has transpired. Both stock and bond investors have had meaningful obstacles to deal with at key turning points. My hope is that our portfolio management thoughts, shared in real-time on the blog, have provided a consistent well of support along the way. Read more